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Height and cancer incidence in the Million Women Study: 
prospective cohort, and meta-analysis of prospective studies 
of height and total cancer risk
Jane Green, Benjamin J Cairns, Delphine Casabonne, F Lucy Wright, Gillian Reeves, Valerie Beral, for the Million Women Study collaborators*
Summary
Background Epidemiological studies have shown that taller people are at increased risk of cancer, but it is unclear if 
height-associated risks vary by cancer site, or by other factors such as smoking and socioeconomic status. Our aim 
was to investigate these associations in a large UK prospective cohort with suﬃ  cient information on incident cancer 
to allow direct comparison of height-associated risk across cancer sites and in relation to major potential confounding 
and modifying factors.
Methods Information on height and other factors relevant for cancer was obtained in 1996–2001 for middle-aged 
women without previous cancer who were followed up for cancer incidence. We used Cox regression models to 
calculate adjusted relative risks (RRs) per 10 cm increase in measured height for total incident cancer and for 
17 speciﬁ c cancer sites, taking attained age as the underlying time variable. We also did a meta-analysis of published 
results from prospective studies of total cancer risk in relation to height. 
Findings 1 297 124 women included in our analysis were followed up for a total of 11·7 million person-years (median 
9·4 years per woman, IQR 8·4–10·2), during which time 97 376 incident cancers occurred. The RR for total cancer 
was of 1·16 (95% CI 1·14–1·17; p<0·0001) for every 10 cm increase in height. Risk increased for 15 of the 17 cancer 
sites we assessed, and was statistically signiﬁ cant for ten sites: colon (RR per 10 cm increase in height 1·25, 95% CI 
1·19–1·30), rectum (1·14, 1·07–1·22), malignant melanoma (1·32, 1·24–1·40), breast (1·17, 1·15–1·19), 
endometrium (1·19, 1·13–1·24), ovary (1·17, 1·11–1·23), kidney (1·29, 1·19–1·41), CNS (1·20, 1·12–1·29), non-
Hodgkin lymphoma (1·21, 1·14–1·29), and leukaemia (1·26, 1·15–1·38). The increase in total cancer RR per 10 cm 
increase in height did not vary signiﬁ cantly by socioeconomic status or by ten other personal characteristics we 
assessed, but was signiﬁ cantly lower in current than in never smokers (p<0·0001). In current smokers, smoking-
related cancers were not as strongly related to height as were other cancers (RR per 10 cm increase in height 1·05, 
95% CI 1·01–1·09, and 1·17, 1·13–1·22, respectively; p=0·0004). In a meta-analysis of our study and ten other 
prospective studies, height-associated RRs for total cancer showed little variation across Europe, North America, 
Australasia, and Asia.
Interpretation Cancer incidence increases with increasing adult height for most cancer sites. The relation between 
height and total cancer RR is similar in diﬀ erent populations.
Funding Cancer Research UK and the UK Medical Research Council.
Introduction
Tall people are at increased risk of cancer. Increasing 
cancer risk with increasing adult height has been reported 
for all cancers combined and for several common cancers, 
such as those of the breast, ovary, prostate, and large 
bowel.1–7 Evidence is limited, however, for incident, rather 
than fatal, disease and for less common cancer sites. 
Moreover, it is not clear to what extent height-associated 
risks vary by cancer site, or how other factors, such as 
smoking and socioeconomic status, aﬀ ect these 
associations.8,9 Because the range of height in a given 
population is usually narrow, large numbers of events 
are needed for reliable estimation of risk. Therefore we 
report here on the relation between height and cancer 
incidence in a prospective cohort study of more than 
1 million middle-aged women in the UK. We also did a 
meta-analysis of published results from prospective 
studies on the relation between height and total cancer 
incidence or mortality.
Methods
Participants
Between 1996 and 2001, 1·3 million middle-aged women 
invited to attend the UK’s National Health Service (NHS) 
Breast Screening Programme completed a Million Women 
Study recruitment questionnaire, which asked, among 
other things, about social, demographic, and lifestyle 
factors, including current height and weight. Of women 
who answered a study questionnaire in 2006–07, a sample 
selected at random (on the basis of day of birth) were asked 
in 2006–09 to have their height measured by their family 
doctor: 3762 women did so. In this validation sample, the 
correlation between measured and reported heights was 
excellent (Pearson correlation coeﬃ  cient 0·88).
For study protocols and 
questionnaires see http://www.
millionwomenstudy.org/
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All participants gave written consent to take part in our 
study, and approval was obtained from the Oxford and 
Anglia Multi-Centre Research Ethics Committee. All 
study participants have a unique NHS number and are 
automatically followed up for death, emigration, and 
cancer registration through the NHS central registers 
with that number and other identifying details. The 
registers regularly provide study investigators with 
information on the date of any such event in participants, 
and code the underlying cause of death and cancer site 
with the International Classiﬁ cation of Diseases, 10th 
revision (ICD-10).10 Follow-up is complete for over 99% of 
study participants. 
Procedures 
Our main endpoints were incident invasive cancer at 
17 individual sites with at least 1000 incident cases: mouth 
and pharynx (ICD-10 C00-C14), oesophagus (C15), 
stomach (C16), colon (C18), rectum (C19-20), pancreas 
(C25), lung (C34), malignant melanoma (C43), breast 
(C50), endometrium (C54), ovary (C56), kidney (C64), 
bladder (C67), central nervous system (C70–72, D32, 33, 
42, and 43), non-Hodgkin lymphoma (C82-85), multiple 
myeloma (C90), and leukaemia (C91-95). We included all 
other invasive cancers (the remaining ICD-10 C codes, 
except non-melanoma skin cancer [C44]) as “other and 
unspeciﬁ ed” cancers.
We deﬁ ned smoking-related cancers as those for which 
the International Agency for Research on Cancer (IARC) 
has concluded there is suﬃ  cient evidence of 
carcinogenicity in human beings in relation to active 
tobacco smoking:11,12 of the sites listed above, mouth and 
pharynx, oesophagus, stomach, colorectum, pancreas, 
lung, mucinous tumours of the ovary, kidney, and myeloid 
leukaemia (C92), and, additionally, liver (C22), larynx, 
nasal cavity and nasal sinuses (C30-32), cervix (C53), and 
urinary tract, including renal pelvis and ureter (C65, 66, 
68). When comparing smoking-related and other cancers, 
we excluded from our analysis cancers of ill-deﬁ ned and 
unspeciﬁ ed sites, which might include some smoking-
related cancers (ICD-10 C26, C39, C57, C76-80 and 
C95-96), and cancers of the ovary (for a substantial 
proportion of which histological subtype was not known, 
and which might have included mucinous tumours).
Height was reported by participants at recruitment in 
feet and inches, and converted to centimetres for our 
analysis. For the analyses, women were divided into six 
categories of reported height (<155 cm [reference group], 
155–159·9 cm, 160–164·9 cm, 165–169·9 cm, 
170–174·9 cm, and 175 cm and taller); we took the average 
height in each of these categories to be the mean 
measured height in that category in the sample whose 
height was measured in 2006–09. Where appropriate, 
mean measured heights are reported standardised to the 
distribution of self-reported heights within the whole 
population, or relevant subgroup. 
We excluded women from our analyses if they had 
any type of cancer other than non-melanoma skin 
 Height in cm* All women
  <155 155 160 165 170 ≥175  
Mean measured height (SD) 152·8 (4·1) 156·5 (2·3) 160·4 (2·9) 164·9 (2·9) 169·0 (2·9) 173·8 (4·3) 160·9 (6·4)†
Characteristics at recruitment
Number of women 233 516 196 773 388 515 288 893 143 289 46 138 1 297 124
Mean age, years (SD) 56·3 (4·9) 56·2 (4·9) 56·2 (4·9) 56·0 (4·8) 56·0 (4·8) 55·8 (4·8) 56·1 (4·9)
Socioeconomic status, n (%) in lowest quintile 59 220 (26%) 42 862 (22%) 73 119 (19%) 48 190 (17%) 23 262 (16%) 7 664 (17%) 19·7
Current smokers, n (%) 50 775 (23%) 40 500 (22%) 72 763 (20%) 51 678 (19%) 26 147 (19%) 8 369 (19%) 20·5
Alcohol intake, n (%) ≥7 units per week 47 138 (20%) 43 324 (22%) 92 126 (24%) 73 597 (26%) 36 742 (26%) 11 734 (26%) 23·7
Body-mass index, n (%) BMI ≥30 54 550 (25%) 38 493 (20%) 65 622 (18%) 42 004 (15%) 18 370 (13%) 5 320 (12%) 18·0
Strenuous exercise, n (%) once a week or more 76 917 (35%) 69 607 (37%) 147 103 (39%) 116 614 (42%) 58 339 (42%) 18 699 (42%) 39·0
Age at menarche, n (%) ≥14 years 79 858 (35%) 69 718 (36%) 139 607 (37%) 108 550 (38%) 57 852 (41%) 20 176 (45%) 37·4
Parity, n (%) nulliparous 22 827 (10%) 19 149 (10%) 40 296 (10%) 33 267 (12%) 17 985 (13%) 6 900 (15%) 10·8
Number of full-term pregnancies, n (%) with three 
or more
82 436 (35%) 67 118 (34%) 127 826 (33%) 91 287 (32%) 44 074 (31%) 13 335 (29%) 32·9
Age at ﬁ rst birth, n (%) ≥25 years 67 250 (33%) 61 042 (35%) 129 031 (38%) 103 017 (41%) 52 677 (43%) 17 492 (46%) 38·2
Postmenopausal, n (%) 162 551 (81%) 136 544 (81%) 269 384 (81%) 197 618 (80%) 97 855 (80%) 30 900 (79%) 80·5
Ever use of oral contraceptives, n (%) 133 979 (58%) 114 105 (59%) 228 669 (60%) 173 520 (61%) 85 522 (60%) 27 571 (60%) 59·5
Current use of HRT, n (%) 75 151 (33%) 63 865 (33%) 128 891 (34%) 98 086 (34%) 48 516 (34%) 15 637 (34%) 33·6
Follow-up for cancer incidence   
Woman-years, millions 2·1 1·8 3·5 2·6 1·3 0·4 11·7
Number of incident cancers 15 792 14 213 28 806 22 571 11 902 4 092 97 376
*The categories of height are those reported at recruitment, and mean values are those measured in a randomly selected sample. †Standardised to the distribution of categories of self-reported height in our 
whole analysis population.
Table 1: Baseline characteristics by height and follow-up for incident cancer in the Million Women Study
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cancer (ICD10 C44) registered before recruitment and if 
they did not have valid information on height at 
recruitment (including a small proportion, about 0·05% 
whose reported height was <120 cm or >200 cm). For 
analyses including endometrial and/or cervical cancers, 
we excluded women if they reported a hysterectomy at 
recruitment, or if their hysterectomy status was 
unknown; similarly, for analyses of ovarian cancer, we 
excluded women if they reported a bilateral 
oophorectomy at recruitment, or if their oophorectomy 
status was unknown.
We calculated woman-years from the date of 
recruitment to the date of ﬁ rst cancer registration (at any 
site), death, or the last date of follow-up, whichever was 
ﬁ rst. For analyses of cancer incidence, the last date of 
follow-up was Dec 31, 2008, for the UK regions of East 
Anglia and South West; June 30, 2008, for Oxford, 
Thames, West Midlands, and North West (Mersey); and 
Dec 31, 2007, for Northern and Yorkshire, Trent, North 
West (Manchester and Lancashire), and Scotland.
Statistical analysis 
We used Cox regression models to estimate relative 
risks (RRs) and CIs in relation to height at recruitment, 
taking attained age as the underlying time variable. We 
stratiﬁ ed all analyses by age at recruitment (<52, 53–55, 
56–58, 59–61, 62–64, ≥65 years) and region (ten regions 
covered by ten cancer registries), and adjusted, as 
appropriate, for quintiles of socioeconomic group (based 
on Townsend deprivation score13), body-mass index 
(<22·5, 22·5–24·9, 25·0–27·4, 27·5–29·9, ≥30 kg/m²), 
strenuous exercise (less than once a week, once a week 
or more), alcohol consumption (none, ≤2 units per 
week, ≥3 units per week), smoking (never, past, current 
1–14 cigarettes per day, current ≥15 cigarettes per day), 
age at menarche (<13, 13, ≥14 years), parity (0, 1–2, 
≥3 full-term pregnancies), and age at ﬁ rst birth (<25, 
≥25 years). We assigned missing values of adjustment 
variables a separate category and did sensitivity analyses 
restricted to women with available information on all 
adjustment variables. Information on all variables was 
that provided at recruitment. 
We calculated the RR per 10 cm increase in height as a 
trend across the six category means using the measured 
mean height in each category of reported height.14 We 
assessed heterogeneity of trends in RRs between diﬀ erent 
cancer sites with a (χ²) contrast test, under the survival 
analysis assumptions that estimates at each cancer site 
are asymptotically normally distributed and, because of 
censoring at ﬁ rst cancer diagnosis at any site, uncorrelated 
(and that therefore site-speciﬁ c estimates account for 
competing risks of cancers at other sites).15 
Where two categories of exposure are compared (as in 
the text) conventional CIs are given. For analyses of total 
cancer, where more than two categories are compared (as 
in the ﬁ gures), ﬂ oated CIs (FCIs) were estimated by 
treating the RRs as ﬂ oating absolute risks (FARs).16,17 Use 
of ﬂ oated methods allows valid comparisons to be made 
between any two exposure groups, even if neither is the 
baseline group. All results are presented in the text with 
95% CIs, but for analyses by cancer site, when multiple 
RRs were estimated, 99% CIs are given in the ﬁ gures.
Where we present results in the form of plots, the RRs 
and their corresponding FCIs or CIs are represented by 
squares and lines with the area of each square inversely 
proportional to the variance of the logarithm of the 
corresponding RR. This shows the amount of statistical 
information involved.
Meta-analysis
We identiﬁ ed published prospective studies of adult 
height and risk of total cancer (incidence or mortality) 
through electronic searches of published work (Medline 
and Embase, up to April, 2011) with combinations of 
the search terms “height”, “body size”, “anthropometr*”, 
“neoplasms”, “mortality”, and “risk factors”, and 
Women Incident 
cancers
RR (95% FCI)
<155 cm (mean 152·8 cm) 233 516 15 792 1·00 (0·98–1·02)
155 cm (mean 156·5 cm) 196 773 14 213 1·08 (1·07–1·10)
160 cm (mean 160·4 cm) 388 515 28 806 1·12 (1·11–1·14)
165 cm (mean 164·9 cm) 288 893 22 571 1·20 (1·18–1·22)
170 cm (mean 169·0 cm) 143 289 11 902 1·28 (1·25–1·30)
≥175 cm (mean 173·8 cm) 46 138 4092 1·37 (1·33–1·42)
Analysis stratiﬁ ed by age at recruitment and region and adjusted for 
socioeconomic status, smoking, alcohol intake, body mass index, strenuous 
exercise, age at menarche, parity, and age at ﬁ rst birth.
Table 2: Relative risks (RRs) and 95% ﬂ oated CIs (FCIs) for total cancer 
incidence, by category of height reported at recruitment (mean 
measured height)
150 155 160 165 170 175
1·0
0
1·1
1·2
1·3
1·4
RR
 (9
5%
 F
CI
)
Mean height (cm)
Figure 1: Relative risks (RRs) and 95% ﬂ oated CIs (FCIs) for total incident 
cancer, by height
RRs are adjusted for age, region, socioeconomic status, smoking, alcohol intake, 
body-mass index, strenuous exercise, age at menarche, parity, and age at ﬁ rst birth, 
and are plotted against the mean measured height in each category. 
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through cited references in identiﬁ ed papers. We did 
not limit our searches by study size, source of study 
population, date, or language of publication. We 
included in our meta-analysis all identiﬁ ed studies with 
published age-adjusted RR and 95% CIs for total cancer 
per 10 cm increase in height, or with suﬃ  cient published 
data to allow estimation of such RRs. Data were 
extracted independently by two researchers (JG and 
BJC). Where only categorical results were published, 
we calculated the trend in RR per 10 cm increase in 
height using the mean height in each height category 
(estimated, where necessary, as category midpoints, or 
by other methods),18 assuming linearity of log RRs and 
with a summary trend estimate obtained by the method 
of generalised least squares.19 We combined results for 
subgroups of total cancer (eg, smoking-related and 
other cancers) by inverse-variance weighted least 
squares, where necessary. For each study we used the 
most fully adjusted RR available. Study-speciﬁ c RRs 
were combined to give summary RRs with weights 
proportional to the inverse of the variance. Where the 
mean year of birth of the study population was not 
given, we made an estimate with the average age at, and 
year of, study recruitment. Where necessary we 
estimated the mean height of the study population 
using mean height within categories and the categorical 
distribution of heights within the study population. For 
all analyses we used Stata (version 11.1).
Role of the funding source
The funding sources did not inﬂ uence the design of the 
study, the collection, interpretation and analysis of the 
data, the preparation of this report, or the decision to 
publish. BJC, DC, and JG had access to the raw data for 
the study. The corresponding author had full access to all 
data and the ﬁ nal responsibility for the decision to submit 
for publication. 
Results 
The 1 297 124 women included in our analysis had a mean 
age at recruitment of 56·1 years (SD 4·9) and an average 
year of birth of 1942. The median length of follow-up was 
9·4 years per woman (IQR 8·4–10·2 years), for a total of 
11·7 million person-years, during which 97 376 incident 
cancers were notiﬁ ed.
Table 1 shows characteristics of the study population, 
including measured height, by six categories of height 
reported at recruitment. Taller women tended to be of 
higher socioeconomic status, to drink more alcohol, to be 
more active, to have a later age at menarche, to have 
fewer children, and to have their ﬁ rst child later in life 
than shorter women. Taller women were less likely to be 
obese or to be current smokers. Based on heights 
measured in the validation sample, the mean height in 
the study population was 160·9 cm (SD 6·4).
Total cancer incidence rose with increasing height 
(table 2). Comparing women in the tallest group with 
RR (95% CI)
Adjusted by age and region only 1·14 (1·13–1·15)
Additionally adjusted separately by
Socioeconomic status 1·15 (1·13–1·16)
Alcohol 1·14 (1·13–1·15)
Smoking 1·15 (1·13–1·16)
Body-mass index 1·15 (1·14–1·17)
Strenuous exercise 1·14 (1·13–1·16)
Age at menarche 1·14 (1·13–1·16)
Parity 1·13 (1·12–1·15)
Age at ﬁ rst birth 1·14 (1·13–1·15)
Adjusted simultaneously for all of the above 1·16 (1·15–1·18)
Analysis restricted to 1 087 489 women (81 797 with cancer) with information on all adjustment variables.
Table 3: Relative risks (RRs) and 95% CIs per 10 cm increase in height, for total incident cancer: eﬀ ect of 
adjustment by various factors
Number of  
incident cancers
RR* & 99% CI
Mouth and pharynx                                   0·94 (0·82–1·08)1095  
Oesophagus                                        1·04 (0·91–1·19)1167  
Stomach                                           1·03 (0·90–1·18)1177  
Colon                                             1·25 (1·17–1·32)6281  
Rectum                                            1·14 (1·05–1·24)3190  
Pancreas                                          1·05 (0·95–1·17)2044  
Lung                                              1·03 (0·98–1·08)8074  
Melanoma                                          1·32 (1·22–1·42)3583  
Breast                                            1·17 (1·14–1·20)39 299 
Endometrium                                       1·19 (1·12–1·26)5810  
Ovary                                             1·17 (1·09–1·25)4830  
Kidney                                            1·29 (1·15–1·45)1665  
Bladder                                           1·00 (0·88–1·14)1354  
CNS                            1·20 (1·09–1·32)2328  
Non-Hodgkin lymphoma                              1·21 (1·12–1·31)3411  
Multiple myeloma                                  1·13 (0·99–1·29)1215  
Leukaemias                                        1·26 (1·11–1·42)1482  
Other and unspecifed                              1·15 (1·10–1·21)8997
Total cancer                                      1·16 (1·14–1·17)97 376 
1·0 1·250·75 1·5
Figure 2: Relative risks (RRs) and 99% CIs per 10 cm increase in height for incident cancer at 17 speciﬁ c sites 
and for total cancer
The doted line represents the RR per 10 cm increase in height for total cancer. *RRs are adjusted for age, region, 
socioeconomic status, smoking, alcohol intake, body-mass index, strenuous exercise, age at menarche, parity, and 
age at ﬁ rst birth.
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those in the shortest group (a diﬀ erence of 21 cm: mean 
measured heights 174 cm and 153 cm), the adjusted RR 
for total incident cancer was 1·37 (95% CI 1·33–1·42; 
p<0·0001). The RR for total cancer was 1·16 (1·14–1·17; 
p<0·0001) per 10 cm increase in height  (ﬁ gure 1).
Figure 2 shows the RRs per 10 cm increase in height for 
the 17 separate cancer sites we assessed, for all other 
cancers and for total cancer. The height-associated RRs 
are greater than 1·0 for 15 of the 17 speciﬁ c sites, and are 
signiﬁ cantly increased for ten speciﬁ c sites and for the 
group of other and unspeciﬁ ed cancers: colon (RR per 
10 cm increase in height 1·25, 95% CI 1·19–1·30), rectum 
(1·14, 1·07–1·22), malignant melanoma (1·32, 1·24–1·40), 
breast (1·17, 1·15–1·19), endometrium (1·19, 1·13–1·24), 
ovary (1·17, 1·11–1·23), kidney (1·29, 1·19–1·41), central 
nervous system (1·20, 1·12–1·29), non-Hodgkin 
lymphoma (1·21, 1·14–1·29), leukaemia (1·26, 1·15–1·38), 
and other cancers (1·15, 1·11–1·20). For no cancer site was 
there a signiﬁ cant decrease in risk with increasing height. 
There is heterogeneity across cancer sites (contrast test χ² 
[17 degrees of freedom]=115·2; p<0·0001) mostly because 
of the greater than average increase in risk with increasing 
height for colon cancer and for malignant melanoma, and 
the lower than average risk for lung cancer. Breast cancer 
accounts for half of incident cancers in our study and the 
results for breast cancer therefore dominate the overall 
results. However, the overall RR of incident cancer in 
relation to height was not materially altered when we 
excluded breast cancer cases from our analysis (RR per 
10 cm increase in height 1·15, 95% CI 1·13–1·16).  
We adjusted our results in ﬁ gures 1 and 2 and in table 2 
by age, region, socioeconomic status, smoking, alcohol, 
body-mass index, physical activity, age at menarche, 
parity, and age at ﬁ rst birth. Table 3 shows the eﬀ ect of 
adjustment by potential confounding variables on the RR 
for total cancer per 10 cm increase in height in an analysis 
restricted to the 1 087 489 women with full information 
on all adjustment variables. Compared with the risk with 
adjustment for age and region only (RR 1·14, 95% CI 
1·13–1·15), additional adjustment by the remaining 
factors increases the RR slightly to 1·16 (1·15–1·18).
Figure 3 shows the RR for total cancer per 10 cm increase 
in height, and the mean measured height, in subgroups of 
women deﬁ ned by their year of birth, socioeconomic 
status, smoking status, alcohol con sumption, body-mass 
index, physical activity, age at menarche, parity, age at ﬁ rst 
birth, menopausal status, and use of oral contraceptives 
and hormone replacement therapy. As we expected, 
women born before 1939 were shorter than women born 
in 1946 or later (mean measured height 159·9 vs 161·5 cm), 
as were women from the lowest compared to the highest 
socioeconomic tertile (160·1 vs 161·4 cm). However, the 
height-associated RR for total cancer did not vary 
signiﬁ cantly by these or by most other characteristics. 
Figure 4 shows this lack of variation by socioeconomic 
status. Although the risk for total cancer is somewhat 
higher in women in the lowest tertile of socioeconomic 
status, the pattern of risk by height is similar in all three 
tertiles. Of the 12 personal characteristics we assessed, 
only smoking status substantially modiﬁ ed the size of the 
height-related RRs (ﬁ gure 3). The RR per 10 cm greater 
height was 1·19 (95% CI 1·17–1·21) in never smokers, but 
only 1·11 (1·08–1·14) in current smokers (p<0·0001 
for hetero geneity). 
Mean measured
height (SD)*
Incident
cancers (N)
RR† (99% CI)
All women                                       97 376   160·9 (6·4) 1·16 (1·14–1·17)
Year of birth                                     
34 660   159·9 (6·4) 1·16 (1·14–1·19)<1939                         
41 456   161·0 (6·4) 1·16 (1·14–1·19)1939–1945                     
21 260   161·5 (6·5) 1·14 (1·10–1·17)1946–1952                     
Socioeconomic group                               
31 229   161·4 (6·3) 1·15 (1·12–1·18)Upper third                   
32 101   161·0 (6·4) 1·18 (1·15–1·21)Middle third                  
33 369   160·1 (6·4) 1·14 (1·12–1·17)Lower third                   
Smoking                                           
42 244   160·9 (6·3) 1·19 (1·16–1·21)Never                         
26 477   161·2 (6·6) 1·16 (1·13–1·20)Past                          
23 602   160·7 (6·4) 1·11 (1·08–1·14)Current
Alcohol                                           
53 485   160·5 (6·4) 1·16 (1·13–1·18)<3 units per week                 
43 138   161·4 (6·4) 1·16 (1·13–1·19)3 or more units per week          
Body-mass index                                   
41 590   161·6 (6·4) 1·15 (1·12–1·17)<25 kg/m2
52 106   160·3 (6·4) 1·16 (1·14–1·19)≥25 kg/m2
Strenuous exercise                                
59 399   160·5 (6·5) 1·16 (1·14–1·18)<Once per week                
34 306   161·4 (6·3) 1·16 (1·13–1·19)Once or more per week         
Age at menarche                                   
37 009   160·2 (6·4) 1·16 (1·14–1·19)<13 years                     
22 884   161·3 (6·4) 1·16 (1·13–1·20)13 years                      
35 528   161·2 (6·4) 1·15 (1·12–1·18)14 years or more              
Parity                                            
65 435   161·0 (6·5) 1·17 (1·15–1·19)<3                            
31 761   160·5 (6·3) 1·15 (1·12–1·18)3 or more                     
Age at ﬁrst birth                                
50 746   160·5 (6·3) 1·17 (1·14–1·19)<25 years                     
32 243   161·3 (6·4) 1·16 (1·13–1·19)25 years or more              
Menopausal status                                 
12 907   161·7 (6·5) 1·15 (1·10–1·19)Pre/peri                      
70 313   160·6 (6·4) 1·16 (1·14–1·18)Post                          
Oral contraceptive use                            
42 665   160·6 (6·4) 1·16 (1·14–1·19)Never                         
53 594   161·0 (6·4) 1·15 (1·13–1·18)Ever                          
Hormone replacement therapy use                   
48 087   160·7 (6·5) 1·16 (1·13–1·18)Never                         
16 940   160·8 (6·2) 1·17 (1·13–1·22)Past                          
34 855   161·1 (6·4) 1·14 (1·11–1·17)Current
  1 1·25
Figure 3: Relative risks (RRs) and 99% CIs per 10 cm increase in height for all incident cancer, by various 
characteristics at recruitment
The dotted line represents the RR per 10 cm increase in height for all women. *Standardised to the distribution of 
self-reported heights within each subgroup of the whole study population. †RRs are adjusted as appropriate for 
age, region, socioeconomic status, smoking, alcohol intake, body-mass index, strenuous exercise, age at 
menarche, parity, and age at ﬁ rst birth. 
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Figure 5 shows the RRs per 10 cm increase in height by 
cancer site in never smokers and in current smokers 
(results in past smokers are uninterpretable, because they 
are a heterogeneous group with a wide range of times 
since last smoking). The mix of cancers diﬀ ers in the two 
groups with, as expected, a higher proportion of women 
with lung and other smoking-related cancers in current 
smokers than in never smokers. In never-smokers, 
heterogeneity across cancer sites was substantially weaker 
(p=0·004) than in current smokers (p<0·0001).
For smoking-related cancers, the RR per 10 cm greater 
height was substantially smaller in current smokers than 
in never smokers (1·05 vs 1·17, p for diﬀ erence=0·0004; 
ﬁ gure 6). By contrast, for other speciﬁ ed cancers height-
associated RRs were similar in current smokers and in 
never smokers, and close to our estimate for smoking-
related cancers in never smokers (ﬁ gure 6).
Published evidence suggests that current smoking is 
not a strong risk factor for colorectal cancer20 and the 
number of these cancers is large, so we undertook a 
sensitivity analysis with colorectal cancer classed as not 
related to smoking (ie, as in the latest full report on 
150 155 160 165 170 175
1·0
0
1·1
1·2
1·3
1·4
RR
 (9
5%
 F
CI
)
Mean height (cm)
Highest socioeconomic third
Middle socioeconomic third
Lowest socioeconomic third
Figure 4: Relative risks (RRs) and 95% ﬂ oated CIs (FCIs) for all incident cancer 
in relation to height, and by socioeconomic status
The baseline category (RR=1·0) is women shorter than 160 cm from the highest 
socioeconomic group. RRs are adjusted for age, region, smoking, alcohol intake, 
body-mass index, strenuous exercise, age at menarche, parity, and age at ﬁ rst 
birth. RRs are plotted against the mean measured height in each category of 
height (<160 cm, 160–165 cm, 165–170 cm, ≥170 cm), within categories of 
socioeconomic status.
Never smokers Current smokers
Number of
incident cancers RR* (99% CI)
Number of
incident cancers RR* (99% CI)
Mouth and pharynx 0·94 (0·73–1·21)351 0·89 (0·71–1·11)443
Oesophagus 1·00 (0·79–1·26)403 0·93 (0·74–1·17)413
Stomach 0·94 (0·74–1·19)407 1·20 (0·94–1·54)345
Colon 1·20 (1·10–1·31)2960 1·27 (1·11–1·46)1119
Rectum 1·20 (1·06–1·35)1493 1·11 (0·92–1·35)556
Pancreas 1·06 (0·90–1·25)804 1·00 (0·83–1·20)630
Lung 1·15 (0·96–1·38)667 1·04 (0·97–1·10)5425
Melanoma 1·34 (1·20–1·49)1943 1·31 (1·06–1·61)478
Breast 1·18 (1·14–1·22)18 533 1·13 (1·07–1·19)7647
Endometrium 1·15 (1·06–1·25)3192 1·18 (1·00–1·40)720
Ovary 1·23 (1·12–1·36)2426 1·04 (0·89–1·22)849
Kidney 1·31 (1·10–1·57)698 1·34 (1·07–1·67)416
Bladder 1·21 (0·97–1·51)438 0·91 (0·74–1·12)495
CNS 1·21 (1·06–1·39)1194 1·28 (1·02–1·61)403
Non-Hodgkin lymphoma 1·22 (1·09–1·37)1630 1·19 (1·00–1·43)651
Multiple myeloma 1·10 (0·91–1·33)610 1·19 (0·86–1·65)197
Leukaemias 1·33 (1·12–1·59)711 1·18 (0·90–1·56)276
Other and unspecifed 1·18 (1·09–1·28)3616 1·16 (1·06–1·27)2472
Total cancer 1·19 (1·16–1·21)42 244 1·11 (1·08–1·14)23 602 
1·0 1·250·75 1·5 1·0 1·250·75 1·5
Figure 5: Relative risks (RRs) and 99% CIs per 10 cm increase in height, for all incident cancer and for incident cancer at 17 speciﬁ c sites, in never and current smokers
Dotted lines represent the RR for total cancer. *RRs are adjusted for age, region, socioeconomic status, alcohol intake, body-mass index, strenuous exercise, age at menarche, parity, and age at ﬁ rst birth. 
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smoking and cancer available from IARC11). The overall 
pattern of RRs remained similar, with lower risk for 
smoking-related cancers than for other cancers in current 
smokers, although the diﬀ erence between these risks 
was reduced (RR per 10 cm height 1·02, 95% CI 
0·97–1·06, in current smokers and 1·10, 1·03–1·17, in 
never smokers; p for diﬀ erence=0·05); for other speciﬁ ed 
cancers, risks remained similar to those in our main 
analysis (RRs 1·18, 1·14–1·22, in current smokers and 
1·19, 1·16–1·21, in never smokers). 
Because breast cancer dominates our ﬁ ndings, we 
repeated our analyses shown in ﬁ gure 3 separately for 
the ﬁ ve most common cancers in our study: breast, lung, 
colon, endometrium, and ovary, and for the remaining 
cancers. Overall, we did not identify signiﬁ cant hetero-
geneity, by the 12 factors we show in ﬁ gure 3, for these 
cancer sites (χ² test for heterogeneity aggregated across 
all characteristics: colon p=0·7, lung p=0·2, breast 
p=0·3, endometrium p=0·5, ovary p=0·2, remaining 
cancers p=0·2).
Because there was no strong variation by cancer site in 
our study except in smokers, we did a meta-analysis of 
published studies of all-cancer risk, noting for each study 
the proportion of current smokers in the study population. 
Figure 7 shows details of our study together with ten other 
prospective studies1,3,8,21–28 that have published results in 
such a way as to allow estimation of the RR of total cancer 
incidence or mortality per 10 cm increase in height. The 
populations covered include men and women from Asia, 
Australasia, Europe, and North America, with mean years 
of birth ranging over three decades (1917 to 1946), and with 
mean heights ranging over 24 cm (155 to 179 cm). The 
overall increase in RR per 10 cm greater height is 1·14 
(95% CI 1·13–1·15). There was no signiﬁ cant heterogeneity 
between the results from studies in men (I² for 
heterogeneity 0%, p=0·9) or between those in women 
(I² for heterogeneity 31%, p=0·2), but there was a slightly 
lower height-associated RR in men than in women (1·10 
vs 1·15, p for diﬀ erence <0·0001). When we excluded the 
ﬁ ndings of our study, the summary RR in women was 
slightly reduced (summary RR per 10 cm greater height 
1·13, 95% CI 1·10–1·16; I² for heterogeneity 25%; p=0·2), 
and there was no longer signiﬁ cant heterogeneity between 
studies in men and those in women (p for diﬀ erence=0·1). 
In our meta-analysis we included studies of cancer 
mortality as well as those of cancer incidence. All of the 
mortality studies we included provided RRs adjusted for at 
least one measure of socioeconomic status, which should 
have minimised potential confounding due to the relation 
in many populations between socioeconomic status and 
cancer survival.29 
Discussion 
We identiﬁ ed a clear and highly signiﬁ cant trend of 
increasing cancer risk with increasing height in this large 
prospective study of UK women, with RR for total incident 
cancer of 1·16 (99% CI 1·14–1·17) for every 10 cm greater 
height. The magnitude of the height-associated increase 
in cancer risk was similar for women with diﬀ erent years 
of birth, from diﬀ erent socioeconomic groups, and across 
subgroups deﬁ ned by alcohol intake, body-mass index, 
physical activity, age at menarche, parity, age at ﬁ rst birth, 
menopausal status, and use of oral contraceptives or 
hormone replacement therapy. By contrast, current 
smokers had a lower RR for total cancer incidence per 
10 cm increase in height than never smokers, and this 
was largely because the height-associated cancer RRs in 
smokers were lower for smoking-related than for other 
cancers. In never smokers, there was only weak variation 
in height-related risk across 17 cancer sites.
This study included more than 97 000 incident cancers. 
Each of the 17 most common speciﬁ c sites we assessed 
included 1000 or more cancers, and together they 
constitute some 90% of total incident cancers in our study 
population. Most previous studies had limited statistical 
power to study site-speciﬁ c cancer risk and tended to focus 
on a few common cancer sites, and our results for the 
common cancers are consistent with their ﬁ ndings.2,4–7
All study participants were routinely linked to records 
of the NHS central registers and details of every incident 
cancer and death were coded before notiﬁ cation to the 
study investigators, thus providing complete and non-
diﬀ erential ascertainment of cancer incidence during 
follow-up. Women were categorised by the height reported 
at recruitment, and height was measured some years later 
in a sample of just over 3700 women. There was excellent 
correlation between self-reported and measured height, 
consistent with previous ﬁ ndings for height and some 
other anthropometric variables in this cohort.30,31 
Nevertheless, we corrected for measurement error, and 
for changes in height over time, by use of the mean 
measured height in each category to calculate RR per 
10 cm increase in height. 
As expected, the average height of women in this 
population was slightly greater the more recently they 
were born and with increasing socioeconomic status 
(ﬁ gure 3). To minimise potential confounding by these 
and other factors relevant for cancer, all analyses compared 
women of a similar age, region of residence, socioeconomic 
Incident
cancers
RR* (95% CI)
Current smokers
7697    1·05 (1·01–1·09)Smoking-related cancers       
8413    1·17 (1·13–1·22)Other cancers                 
Never smokers
6731    1·17 (1·12–1·22)Smoking-related cancers       
22 832 1·18 (1·15–1·21)Other cancers                 
1 1·25
Figure 6: Relative risks (RRs) and 95% CIs per 10 cm increase in height for incident smoking-related and other 
speciﬁ ed cancers, in never and in current smokers
*RRs are adjusted for age, region, socioeconomic status, alcohol intake, body-mass index, strenuous exercise, age 
at menarche, parity, and age at ﬁ rst birth.
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group, age at menarche, parity, age at ﬁ rst birth, body-
mass index, physical activity, smoking status, and alcohol 
consumption. Because of the large size of this study we 
were also able to undertake subgroup analyses by 
12 potential confounding factors, in particular by 
socioeconomic status. Women in higher socioeconomic 
groups are on average taller (table 1), and socioeconomic 
status is related to total cancer incidence (ﬁ gure 4),29 yet 
the association between height and risk of cancer was 
similar for women of low, medium, and high socio-
economic status. As in other studies that could adjust for 
a range of potential confounding factors, our results 
suggest that the relation between height and cancer risk 
is not due to other known risk factors for cancer.9 
Our ﬁ ndings show that the height-related RR of cancer 
was lower for smoking-related cancers than for other 
cancers, but only in current smokers. In accordance with 
our ﬁ ndings Kabat and colleagues32 have reported that 
lung cancer incidence in the Women’s Health Initiative 
study showed a stronger association with height in never 
smokers than in current or past smokers. Our test for 
potential modiﬁ cation of height-related cancer risks by 
smoking status used a multiplicative model. However, 
on an absolute scale there is little diﬀ erence between 
current and never smokers in the excess cancer incidence 
rates. Smoking-related cancers are more common in 
current smokers than in never smokers, with age-
standardised incidence rates of 599 and 176, respectively 
per 100 000 women per year, in this cohort. The estimated 
excess age-standardised incidence rate for every 10 cm 
increase in height for smoking-related cancers is about 
30 per 100 000 women per year, both in current and in 
never smokers (599 × 0·05 for current smokers and 
176 × 0·17 for never smokers).
We found no other modiﬁ cation of height-associated RR 
by the 11 other factors we assessed, either for total cancer, 
or separately for the ﬁ ve most common cancers (breast, 
lung, colon, endometrium, and ovary). However, even in 
our large study we had limited power to assess modiﬁ cation 
of height-related risk by these factors. 
There was little variation in height-associated RRs at 
speciﬁ c cancer sites in never smokers, in whom the eﬀ ect 
of height on cancer risk is free from modiﬁ cation by 
smoking. Most other studies have not made direct 
Mean year
of birth*
Mean
height (cm)
Proportion of
current smokers
Cancer
outcome
Number of
cancers
RR (95% CI)
per 10 cm increase
Men                 
Batty (UK, 2006)3 1917 175 42%  1·10 (1·05–1·16)    Mortality 3101
Davey–Smith (UK, 2000)21 1919 170 57%  1·07 (0·98–1·18)    Mortality 997
Tulinius (Iceland, 1997)22 1924 177 54%† 1·10 (1·03–1·20)    Incidence 1785 
Giovannucci (USA, 2004)23‡ 1928 176 20%  1·11 (1·04–1·17)    Incidence 3270
Hebert (USA, 1997)24§ 1929 178 10%  1·10 (1·04–1·17)    Incidence 2566
Albanes (USA, 1988)1 1931 174 40%  1·28 (1·06–1·56)    Incidence 341
Jousilahti (Finland, 2000)25 1935 172 47%  1·04 (0·91–1·18)    Mortality 659
Batty (Australasia, 2010)26,27 1936 179 NA 1·10 (1·03–1·17)    Mortality 1951
Okasha (UK, 2000)28 1938 175 34%  0·98 (0·79–1·21)    Mortality 311
Sung (South Korea, 2009)8 1943 168 53%  1·10 (1·06–1·12)    Incidence 23 725
Batty (Asia, 2010)26,27 1946 168 NA 1·07 (1·00–1·14)    Mortality 3281
All men                                 1·10 (1·08–1·12)    
Women               
Davey–Smith (UK, 2000)21 1919 158 47%  1·08 (0·96–1·21)    Mortality 848
Tulinius (Iceland, 1997)22 1925 164 41%** 1·10 (1·01–1·22)    Incidence 1490
Albanes (USA, 1988)1 1935 161 30%  1·08 (0·88–1·32)    Incidence 302
Jousilahti (Finland, 2000)25 1935 158 14%  0·96 (0·84–1·10)    Mortality 441
Batty (Australasia, 2010)26,27 1938 161 NA 1·19 (1·08–1·30)    Mortality 1131
Okasha (UK, 2000)28 1939 163 20%  0·89 (0·57–1·40)    Mortality 77
Million Women Study (UK, 2011)          1942 161 20%  1·16 (1·14–1·17)    Incidence 97 376
Batty (Asia, 2010)26,27 1943 156 NA 1·14 (1·02–1·24)    Mortality 1134
Sung (South Korea, 2009)8 1943 155 3%  1·14 (1·10–1·19)    Incidence 9443
All women                               1·15 (1·14–1·17)    
Total               1·14 (1·13–1·15)    
1 21·50·75
Figure 7: Meta-analysis of results from prospective studies: study-speciﬁ c and summary relative risks (RRs) and 95% CIs for all cancer per 10 cm increase in height
The dotted lines represent the summary RRs. NA=not available. *Mean years of birth estimated as necessary. †Includes 24% (men) and 2% (women) pipe or cigar smokers. ‡Category midpoints used to 
estimate mean heights in height categories. §Method of Chêne and Thompson18 used to estimate mean heights in height categories.
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comparisons across cancer sites or between smokers and 
non-smokers. In general, studies have found taller people 
to be at increased risk of a range of cancers with varying 
causes, with no individual cancer site consistently 
identiﬁ ed as showing no association.2,4–7 Our ﬁ nding of 
diﬀ erences in height-related RR between smokers and 
never smokers might provide an explanation for some 
reported inconsistencies in height-associated risk for 
smoking-related cancers.2
Our meta-analysis of height and total cancer risk 
shows that ﬁ ndings are very consistent for incidence 
and for mortality, and in populations from Europe, 
North America, Asia, and Australasia with mean years 
of birth ranging over 30 years, and with mean heights 
ranging from 155 cm to 179 cm. Women in these studies 
were less likely than men to be current smokers (ﬁ gure 7) 
and this might partly explain the slightly higher height-
associated RR in women than in men in our meta-
analysis. The overall result in women is also strongly 
weighted by the results from the Million Women Study, 
in which there has been allowance for measurement 
error, and more extensive adjustment than in the other 
studies, both of which tended to increase the estimated 
RR. As in any meta-analysis of published data, our 
ﬁ ndings need to be interpreted in the knowledge that 
other studies with relevant data might not have 
published their results. 
The similarity of the height-associated RR for diﬀ erent 
cancers and in diﬀ erent populations suggests that a basic 
common mechanism, possibly acting in early life, might 
be involved.8 Adult height reaches its maximum between 
the ages of 20 and 30 years. Variation in height relates to 
genetic and environmental inﬂ uences acting mostly in 
the ﬁ rst 20 years, or so, of life; environmental factors, 
including childhood nutrition and infections, are  believed 
to predominate.33–36 Hormone levels, especially of growth 
factors such as insulin-like growth factors (IGFs), both in 
childhood and in adult life, might be relevant.2,9 Circulating 
levels of IGFs in adulthood and childhood aﬀ ect cancer 
risk;37–40 IGF-I levels in childhood and adolescence are 
strongly related to skeletal growth,38 and levels in 
adulthood, although less strongly, to adult height.41,42 
Another possibility is that height predicts cancer risk 
because taller people have more cells (including stem 
cells), and thus a greater opportunity for mutations 
leading to malignant transformation.43,44 Height might 
thus be related to cancer risk through increased cell 
turnover mediated by growth factors, or through increased 
cell numbers. 
The relation between height and cancer risk might 
underlie part of the diﬀ erence in cancer incidence 
between populations, and changes in cancer incidence 
over time. Adult height in European populations has 
increased by about 1 cm per decade throughout the 
20th century.33,45,46 The increase in adult height during the 
past century could thus have resulted in an increase in 
cancer incidence some 10–15% above that expected if 
population height had remained constant. This assumes, 
of course, that the eﬀ ect of height is independent of 
changes in other risk factors. 
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